CathVision Secures $9 Million in Funding to Accelerate Adoption of ECGenius System & CARDIALYTICS AI-Suite
COPENHAGEN, Denmark, July 18, 2023 /PRNewswire/ -- CathVision, a medical technology company developing innovative electrophysiology solutions designed to support clinical decision making in the EP lab, today announced its most recent financing round of $9 million from investors.
- The ECGenius System includes a proprietary hardware amplifier capable of acquiring high-fidelity, low-noise cardiac electrograms.
- The ECGenius System received FDA 510(k) clearance in May 2022 and is currently available.
- CathVision has achieved several key milestones since the announcement of its last funding round in August 2022, including:
The ECGenius System is commercially available in the United States. - For more information about the ECGenius System, please visit www.cathvision.com/ep-recording-enhanced or email [email protected] .